Keyphrases
Post-transplant Lymphoproliferative Disorder
100%
Rituximab Therapy
100%
Solid Organ Transplant
100%
R-CHOP
100%
Odds Ratio
42%
Initial Treatment
42%
Overall Survival
28%
High-risk Disease
28%
Histology
21%
Complete Remission
21%
Advanced Stage
14%
Treatment-related Mortality
14%
Remission
14%
Partial Remission
14%
Survival Outcomes
14%
Solid Organ Transplantation
14%
Performance Status 2
14%
Low-risk Disease
14%
Elevated LDH
14%
ECOG Performance Status
14%
B Cells
7%
Liver
7%
No Significant Difference
7%
Response Rate
7%
High Risk
7%
Multivariate Analysis
7%
Prognostic Value
7%
Event-free Survival
7%
Poor Outcome
7%
Improved Survival
7%
Novel Therapeutics
7%
6-cycles
7%
Transplant Recipients
7%
Hodgkin
7%
Relapsed Disease
7%
Pathological Diagnosis
7%
T-cell Lymphoma
7%
Age 50
7%
Overall Response Rate
7%
Progression-free Survival
7%
Median Time
7%
Diffuse Large B Cell
7%
Rate 1
7%
Prognostic Score
7%
Biopsy-proven
7%
Low-risk Group
7%
First-line Therapy
7%
Relative Efficacy
7%
Relative Toxicity
7%
Tumor Histology
7%
Cardiothoracic
7%
Baseline Factors
7%
Disease Subtypes
7%
Baseline Predictors
7%
Extranodal Disease
7%
Plasmablastic
7%
Multivariate Logistic Models
7%
Optimal Selection
7%
HR 4.0
7%
Medicine and Dentistry
Transplantation
100%
Monotherapy
100%
Posttransplant Lymphoproliferative Disease
100%
Rituximab
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Diseases
85%
Odds Ratio
42%
Overall Survival
28%
Epstein Barr Virus
21%
B Cell
14%
Lactate Dehydrogenase
14%
Solid Organ Transplantation
14%
Electrocorticography
14%
Biopsy Technique
7%
Infusion
7%
Event Free Survival
7%
T-Cell Lymphoma
7%
Spontaneous Remission
7%
Multivariate Analysis
7%
Retrospective Study
7%
Cardiothoracics
7%
Progression Free Survival
7%
Low Risk Population
7%
Tumor Histology
7%
Histology
7%
Nursing and Health Professions
Transplantation
100%
Monotherapy
100%
Rituximab
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Posttransplant Lymphoproliferative Disease
100%
Diseases
85%
Remission
50%
Odds Ratio
42%
Overall Survival
28%
Organ Transplantation
14%
Lactate Dehydrogenase
14%
Electrocorticography
14%
Multivariate Analysis
7%
Neoplasm
7%
Event Free Survival
7%
Biopsy Technique
7%
Infusion
7%
Low Risk Population
7%
Progression Free Survival
7%
T Cell Lymphoma
7%
Histology
7%
Immunology and Microbiology
Rituximab
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Overall Survival
28%
Epstein Barr Virus
21%
B Cell
14%
Solid Organ Transplantation
14%
T Cell
7%
Event Free Survival
7%
Progression Free Survival
7%
Low Risk Population
7%